<DOC>
	<DOCNO>NCT02394535</DOCNO>
	<brief_summary>The goal clinical research study find high tolerable dose Abraxane™ ( nab-paclitaxel ) give combination capecitabine radiation therapy patient pancreatic cancer . The safety drug drug combination also study .</brief_summary>
	<brief_title>Combining Abraxane With Capecitabine Radiation Therapy Consolidation Treatment Following Induction Chemotherapy Locally Advanced Pancreatic Cancer</brief_title>
	<detailed_description>Study Groups : If find eligible take part study , assign dose level nab-paclitaxel base join study . Up 3 dose level nab-paclitaxel test . About 3-6 participant enrol dose level . The first group participant receive low dose level . Each new group receive high dose group , intolerable side effect see . This continue high tolerable dose nab-paclitaxel found . You receive standard dos radiation therapy capecitabine . Study Drug Administration : You receive nab-paclitaxel vein 30 minute 1 time week 5½ week ( 5 dos total ) . You receive radiation therapy 1 time day Monday Friday 5½ week ( 28 dos ) capecitabine mouth 2 time day . You receive separate consent form describe radiation therapy , capecitabine , risk , additional dosing instruction ( capecitabine ) . Study Visits : Each week radiation therapy : - You physical exam . - Blood ( 2 teaspoon ) draw routine test . - You fill questionnaire . - If take phenytoin , blood ( 1 teaspoon ) drawn check amount phenytoin blood . - If take blood thinner , blood ( 1 teaspoon ) drawn check well blood clot . At one time study , leftover tumor tissue previous biopsy collect test certain type protein ( SMAD4 ) tissue may predict disease come back . Depending SMAD4 status , study doctor may able predict body ( either pancreas different part body ) disease may come back . Length Study : You may continue take nab-paclitaxel , radiation therapy , capecitabine 5½ week . If disease appear get good end-of-treatment visit ( describe ) may able continue take nab-paclitaxel 1 time week , unless disease appear get bad . You longer able take nab-paclitaxel disease get bad , intolerable side effect occur , unable follow study direction . Your participation study end-of-treatment visit . End-Of-Treatment Visit : About 4-6 week finish radiation therapy , end-of-treatment visit . At visit : - You physical exam . - Blood ( 2 tablespoon ) draw routine test . - If take phenytoin , blood ( 1 teaspoon ) drawn check amount phenytoin blood . - If take blood thinner , blood ( 1 teaspoon ) drawn check well blood clot . - You x-ray chest either MRI CT scan abdomen check status disease . - You fill questionnaire . Follow-up Visits : You study visit every 3 month +/- 1 month . At study visit : - You physical exam . - Blood ( 2 tablespoon ) draw routine test . - You MRI CT scan chest x-ray check status disease . If study doctor think tumor ( ) remove , surgery . You give separate consent form describe type surgery risk . This investigational study . Nab-paclitaxel capecitabine FDA-approved commercially available treatment pancreatic cancer . Radiation therapy deliver use FDA-approved commercially available method . It consider investigational give capecitabine nab-paclitaxel together pancreatic cancer . The study doctor explain study drug design work . Up 30 participant take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>1 . ECOG performance status 0 1 2 . Patients must &gt; 18 year age . There upper age restriction . 3 . Cytologic histologic proof adenocarcinoma pancreas . Patients tumor locally advanced borderline resectable . Unequivocal metastasis Islet cell tumor eligible . 4 . All patient must stag physical exam , CXR , contrastenhanced helical thincut abdominal CT. Unresectability define CT criterion : ) evidence tumor extension celiac axis superior mesenteric ( SM ) artery , b ) evidence either CT angiogram occlusion SM vein SM/ portal vein confluence . 5 . Patients must receive prior induction chemotherapy least 2 month 6 month . At least three week elapse last chemotherapy . 6 . Patients must adequate bone marrow function : Platelets &gt; 100,000 cells/mm3 , Hemoglobin &gt; 9.0g/dL ANC &gt; /= 1,500 cells/mm3 . 7 . Hepatic function : Bilirubin &lt; /= 1.5 mg/dL . Patients must adequate liver function : AST ALT &lt; 2.5 X upper limit normal , alkaline phosphatase &lt; 2.5 X upper limit normal . 8 . Renal function : BUN &lt; 30 mg/dL , creatinine &lt; /=1.5 mg/dL creatinine clearance &gt; 30ml/min ( estimate calculate CockcroftGault equation ) . 9 . Patients must sign informed consent indicate aware investigational nature study , aware participation voluntary . 10 . Patients must &lt; Grade 2 preexist peripheral neuropathy ( per CTCAE ) 11 . Patients must recovery clinically significant , nonhematologic toxicity &lt; /= Grade 2 . 12 . Women childbearing potential sexually active male must use effective contraception method treatment three month complete treatment . 13 . Negative serum urine betahCG pregnancy test screen female patient childbearing potential . 1 . Prior abdominal radiotherapy 2 . Current , recent ( within 4 week first infusion study ) , plan participation experimental drug study . 3 . Prior severe infusion reaction ( bronchospasm , stridor , urticaria and/or hypotension ) taxane therapy . 4 . Prior unanticipated severe reaction fluoropyrimidine therapy know hypersensitivity 5fluorouracil . 5 . Prior history cancer within last three year except basal cell carcinoma skin carcinoma situ cervix . Patients previous malignancy without evidence disease 3 year allow enter trial . 6 . Pregnant lactating woman . Women childbearing potential either positive pregnancy test baseline . Women / men childbearing potential use reliable contraceptive method ( oral contraceptive , hormonal contraceptive , intrauterine device , diaphragm condom ) . ( Postmenopausal woman must amenorrheic least 12 month consider nonchildbearing potential ) . Patients must agree continue contraception 30 day date last study drug administration . 7 . Lack physical integrity upper gastrointestinal tract , malabsorption syndrome inability swallow . 8 . Known , exist uncontrolled coagulopathy , INR &gt; 1.5 . 9 . Patients Coumadin must change Lovenox least 1 week prior start capecitabine . Low dose ( 1 mg ) Coumadin allow . Intravenous lowmolecular weight heparin permit . 10 . Patients take Sorivudine Brivudine must drug 4 week prior start capecitabine . Patients take cimetidine must drug discontinue . Ranitidine drug another antiulcer class substitute cimetidine necessary . If patient currently receive allopurinol , must discuss PI see another agent may substitute . 11 . Inability comply study and/or followup procedure 12 . History interstitial lung disease , history slowly progressive dyspnea unproductive cough , sarcoidosis , silicosis , idiopathic pulmonary fibrosis pulmonary hypersensitivity pneumonitis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Pancreatic Cancer</keyword>
	<keyword>Adenocarcinoma pancreas</keyword>
	<keyword>Locally Advanced Pancreatic Cancer</keyword>
	<keyword>Abraxane</keyword>
	<keyword>Nab-Paclitaxel</keyword>
	<keyword>Paclitaxel ( Protein-Bound )</keyword>
	<keyword>ABI-007</keyword>
	<keyword>Radiation therapy</keyword>
	<keyword>XRT</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>Xeloda</keyword>
	<keyword>Questionnaires</keyword>
	<keyword>Surveys</keyword>
</DOC>